Sp389
PANEL DISCUSSION
Date
May 19, 2024
Explore related products in the following collection:
Presenters
University of Chicago Division of the Biological Sciences
BIDMC
Icahn School of Medicine Mount Sinai Hospital
Cleveland Clinic
Tracks
Related Products
RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN’S DISEASE.
INTRODUCTION: Recent guidelines propose a fecal calprotectin (FCP) monitoring strategy in the year after Crohn’s disease (CD) resection for low-risk individuals or those receiving pharmacologic prophylaxis to prevent postoperative recurrence (POR)…
ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED CANCER RATES IN IBD PATIENTS
Oral small molecules (OSM) have demonstrated effectiveness in treating IBD. Certain studies have associated certain OSM with an increased cancer risk. We aimed to assess the cancer risk in IBD patients treated with OSM…
IMIBD Late Breakers and Innovations in IBD
SOCIETY: AGA By popular demand, this new session highlights the best late-breakers submitted to the IBD section and well as innovations in technology and new paradigms of care in IBD
